AllSci News
Sanofi’s subcutaneous Sarclisa cleared in EU for multiple myeloma via on-body injector
The European Commission has approved Sarclisa (isatuximab) subcutaneous as the first anticancer therapy in the EU to be administered via an on-body…
Boehringer posts detailed data from survodutide Phase III showing visceral and liver fat reduction
Boehringer Ingelheim reported detailed Phase III results for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist licensed from Denmark-based...
Hangzhou Sciwind's cAMP-biased GLP-1 ecnoglutide outperforms semaglutide in Phase II
Interim data from a Phase II head-to-head trial reported by China-based Hangzhou Sciwind Biosciences show that ecnoglutide (also known as XW003), the...
Autobahn on track for novel thyroid receptor agonist against bipolar depression after positive Phase II
San Diego-based Autobahn Therapeutics reported positive topline results from its Phase II AMPLIFY-BD trial of elunetirom (ABX-002) in bipolar depression,...
Pfizer's berobenatide demonstrates nearly 16% weight loss in Phase IIb obesity trial data
Pfizer (NYSE: PFE) presented detailed Phase IIb data at the American Diabetes Association's 86th Scientific Sessions showing that berobenatide (PF-3944;...
EU expands label for Chiesi’s Lojuxta to children with ultra-rare cholesterol disorder
The European Commission has approved an expanded indication for Italy-based Chiesi’s Lojuxta (lomitapide) to include children aged 5 years and older with…
Hopstem’s neural progenitor cell injection earns FDA RMAT designation for chronic stroke
Houston-based Hopstem Biotechnology announced receipt of a Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for hNPC01, an iPSC-derived human…
China’s NMPA approves Vcare PharmaTech’s eratrectinib for NTRK fusion-positive solid tumors
China’s NMPA has granted marketing approval to eratrectinib (VC004), a next-generation TRK inhibitor developed by Nanjing-based Jiangsu Vcare PharmaTech Co., Ltd., for…
Bayer posts Phase III data showing Kerendia's kidney benefit in non-diabetic CKD
Bayer's finerenone (Kerendia), a non-steroidal mineralocorticoid receptor antagonist, delivered statistically significant improvements in kidney function...
Otsuka's Voyxact on course for full approval in IgA nephropathy after positive Phase III
Twelve-month eGFR data from the Phase III VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy show that Otsuka's anti-APRIL monoclonal antibody...
Gilead, Lakefront complete USD 2.175b acquisition of Ouro Med targeting BCMAxCD3 BsAb gamgeramig
Gilead Sciences (Nasdaq: GILD) and Belgium-based Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) have completed the joint acquisition of Ouro...
Stipple Bio partners with Lonza on multi-target ADC platform for precision oncology therapies
Cambridge, Massachusetts-based Stipple Bio, Inc. has entered a multi-target license agreement with Switzerland-based Lonza (SIX: LONN) to access the CDMO's...
Made Scientific and Pluristyx launch integrated iPSC development and manufacturing partnership
Princeton, New Jersey-based Made Scientific, Inc., a cell therapy contract development and manufacturing organization backed by South Korea's GC...
Pfizer signs up to access Chai Discovery's generative AI platform for next-gen antibody design
Pfizer (NYSE: PFE) has licensed San Francisco-based Chai Discovery's generative AI platform — including early access to Chai-3, a previously undisclosed...
Biogen’s once-yearly antisense oligonucleotide receives FDA BTD status for spinal muscular atrophy
Biogen (Nasdaq: BIIB) revealed that the US FDA has granted salanersen (BIIB115) Breakthrough Therapy Designation (BTD) for the treatment of spinal muscular…
The AllSci Brief
Free, systematic R&D and deal news. Daily.